MedPath

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Phase 2
Terminated
Conditions
Refractory Multiple Myeloma
Interventions
Registration Number
NCT01078441
Lead Sponsor
National Cancer Institute (NCI)
Brief Summary

This phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide may kill more cancer cells.

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate the 1-year survival of patients with relapsed multiple myeloma treated with bortezomib, liposomal doxorubicin, dexamethasone, and cyclophosphamide.

SECONDARY OBJECTIVES:

I. To evaluate response rates in patients treated with this regimen.

II. To evaluate the median time to progression in patients treated with this regimen.

III. To evaluate the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Peripheral blood and bone marrow samples may be collected for future research. Patients complete the Functional Assessment of Cancer Therapy (FACT) neurotoxicity questionnaire periodically.

After completion of study treatment, patients are followed up every 3 months for 3 years.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
2
Inclusion Criteria
  • Diagnosis of multiple myeloma that was symptomatic at the time of initial diagnosis

  • Must have met the following criteria at one point during the disease course:

    • Bone marrow plasmacytosis with ≥ 10% plasma cells or sheets of plasma cells or biopsy-proven plasmacytoma

    • Symptomatic disease at initial diagnosis that prompted the initiation of therapy as well as evidence of end-organ damage at the time of diagnosis, including at least 1 of the following:

      • Anemia
      • Hypercalcemia
      • Bone disease (lytic bone lesions or pathologic fracture)
      • Renal dysfunction
  • Disease relapsed < 12 months after autologous stem cell transplantation (SCT)

  • Measurable disease, as defined by the presence of ≥ 1 of the following:

    • Serum M-spike ≥ 1 g/dL
    • Urine M-spike ≥ 200 mg/24 hours
    • Involved free light chain (FLC) ≥ 10 mg/dL (provided the serum FLC is abnormal)
    • Plasma cells ≥ 30%
  • ECOG performance status 0-2

  • Negative pregnancy test

  • Fertile patients must use effective contraception

  • At least 14 days since prior palliative and/or localized radiotherapy

  • Left ventricular ejection fraction (LVEF) normal by Echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan

  • Hemoglobin > 8 g/dL

  • Platelet count ≥ 75,000/mm^3 (without transfusion support)

  • Absolute neutrophil count (ANC) ≥ 1,000/mm^3 (without use of growth factors)

  • Creatinine < 2.5 mg/dL

  • Direct bilirubin ≤ 1.5 mg/dL

  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal

  • All tests below must be performed within 14 days prior to registration:

    • Serum free light chain assay
    • Kappa free light chain
    • Lambda free light chain
  • Prior malignancy allowed provided it was treated curatively and has not relapsed in 5 years

    • Patients with basal cell skin cancer, in situ cervical cancer, or prostate cancer not requiring therapy are eligible
Read More
Exclusion Criteria
  • Therapy for relapsed disease following SCT

  • Known allergy to bortezomib or anthracyclines

  • Prior allogeneic SCT

  • Peripheral neuropathy ≥ grade 2 according to the Cancer Therapy Evaluation Program (CTEP) active version of the NCI Common Terminology Criteria for Adverse Events (CTCAE)

  • Concurrent uncontrolled illness that would limit study compliance, including the following:

    • Uncontrolled hypertension
    • Symptomatic congestive heart failure
    • Unstable angina
    • Uncontrolled cardiac arrhythmia
    • Uncontrolled psychiatric illness or social situation
    • Active uncontrolled infection
  • Prior doxorubicin hydrochloride exposure > 240 mg/m^2

  • Active, uncontrolled seizure disorder

  • Seizures within the past 6 months

  • Pregnant or nursing

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Treatment (combination chemotherapy)liposomal doxorubicinPatients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Treatment (combination chemotherapy)bortezomibPatients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Treatment (combination chemotherapy)cyclophosphamidePatients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Treatment (combination chemotherapy)dexamethasonePatients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measures
NameTimeMethod
One-year Survival in Patients Treated With This Regimen.Assessed at 1 year

Proportion of patients who are still alive at 1 year after registration.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (130)

Graham Hospital Association

🇺🇸

Canton, Illinois, United States

Mason District Hospital

🇺🇸

Havana, Illinois, United States

Mayo Clinic in Arizona

🇺🇸

Scottsdale, Arizona, United States

Penrose-Saint Francis Healthcare

🇺🇸

Colorado Springs, Colorado, United States

Saint Mary's Hospital and Regional Medical Center

🇺🇸

Grand Junction, Colorado, United States

Swedish Medical Center

🇺🇸

Englewood, Colorado, United States

North Colorado Medical Center

🇺🇸

Greeley, Colorado, United States

Longmont United Hospital

🇺🇸

Longmont, Colorado, United States

Saint Anthony Hospital

🇺🇸

Lakewood, Colorado, United States

Littleton Adventist Hospital

🇺🇸

Littleton, Colorado, United States

McKee Medical Center

🇺🇸

Loveland, Colorado, United States

Parker Adventist Hospital

🇺🇸

Parker, Colorado, United States

Saint Mary Corwin Medical Center

🇺🇸

Pueblo, Colorado, United States

Beebe Medical Center

🇺🇸

Lewes, Delaware, United States

Exempla Lutheran Medical Center

🇺🇸

Wheat Ridge, Colorado, United States

North Suburban Medical Center

🇺🇸

Thornton, Colorado, United States

Christiana Care Health System-Christiana Hospital

🇺🇸

Newark, Delaware, United States

Saint Joseph Medical Center

🇺🇸

Bloomington, Illinois, United States

Medical Center of Central Georgia

🇺🇸

Macon, Georgia, United States

Eureka Hospital

🇺🇸

Eureka, Illinois, United States

Memorial Hospital

🇺🇸

Carthage, Illinois, United States

Illinois CancerCare Galesburg

🇺🇸

Galesburg, Illinois, United States

Mcdonough District Hospital

🇺🇸

Macomb, Illinois, United States

Community Cancer Center Foundation

🇺🇸

Normal, Illinois, United States

Bromenn Regional Medical Center

🇺🇸

Normal, Illinois, United States

Ottawa Regional Hospital and Healthcare Center

🇺🇸

Ottawa, Illinois, United States

Proctor Hospital

🇺🇸

Peoria, Illinois, United States

Illinois Oncology Research Association CCOP

🇺🇸

Peoria, Illinois, United States

Pekin Cancer Treatment Center

🇺🇸

Pekin, Illinois, United States

Illinois CancerCare-Peoria

🇺🇸

Peoria, Illinois, United States

OSF Saint Francis Medical Center

🇺🇸

Peoria, Illinois, United States

Perry Memorial Hospital

🇺🇸

Princeton, Illinois, United States

Medical Oncology and Hematology Associates-West Des Moines

🇺🇸

Clive, Iowa, United States

Iowa Methodist Medical Center

🇺🇸

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates-Laurel

🇺🇸

Des Moines, Iowa, United States

Iowa Oncology Research Association CCOP

🇺🇸

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates-Des Moines

🇺🇸

Des Moines, Iowa, United States

Iowa Lutheran Hospital

🇺🇸

Des Moines, Iowa, United States

Mercy Medical Center - North Iowa

🇺🇸

Mason City, Iowa, United States

Mercy Medical Center - Des Moines

🇺🇸

Des Moines, Iowa, United States

Siouxland Hematology Oncology Associates

🇺🇸

Sioux City, Iowa, United States

Mercy Medical Center-Sioux City

🇺🇸

Sioux City, Iowa, United States

Saint Luke's Regional Medical Center

🇺🇸

Sioux City, Iowa, United States

Cancer Center of Kansas - Chanute

🇺🇸

Chanute, Kansas, United States

Cancer Center of Kansas - Dodge City

🇺🇸

Dodge City, Kansas, United States

Cancer Center of Kansas - Fort Scott

🇺🇸

Fort Scott, Kansas, United States

Cancer Center of Kansas-Kingman

🇺🇸

Kingman, Kansas, United States

Lawrence Memorial Hospital

🇺🇸

Lawrence, Kansas, United States

Cancer Center of Kansas - El Dorado

🇺🇸

El Dorado, Kansas, United States

Cancer Center of Kansas-Independence

🇺🇸

Independence, Kansas, United States

Cancer Center of Kansas-Liberal

🇺🇸

Liberal, Kansas, United States

Cancer Center of Kansas - Salina

🇺🇸

Salina, Kansas, United States

Cancer Center of Kansas - McPherson

🇺🇸

McPherson, Kansas, United States

Cancer Center of Kansas - Newton

🇺🇸

Newton, Kansas, United States

Cancer Center of Kansas - Parsons

🇺🇸

Parsons, Kansas, United States

Cancer Center of Kansas-Wichita Medical Arts Tower

🇺🇸

Wichita, Kansas, United States

Cancer Center of Kansas - Pratt

🇺🇸

Pratt, Kansas, United States

Cancer Center of Kansas - Wellington

🇺🇸

Wellington, Kansas, United States

Associates In Womens Health

🇺🇸

Wichita, Kansas, United States

Cancer Center of Kansas - Main Office

🇺🇸

Wichita, Kansas, United States

Via Christi Regional Medical Center

🇺🇸

Wichita, Kansas, United States

Cancer Center of Kansas - Winfield

🇺🇸

Winfield, Kansas, United States

Wichita CCOP

🇺🇸

Wichita, Kansas, United States

Union Hospital of Cecil County

🇺🇸

Elkton MD, Maryland, United States

Bixby Medical Center

🇺🇸

Adrian, Michigan, United States

Hickman Cancer Center

🇺🇸

Adrian, Michigan, United States

Community Cancer Center of Monroe

🇺🇸

Monroe, Michigan, United States

Mercy Memorial Hospital

🇺🇸

Monroe, Michigan, United States

Fairview Ridges Hospital

🇺🇸

Burnsville, Minnesota, United States

Mercy Hospital

🇺🇸

Coon Rapids, Minnesota, United States

Fairview-Southdale Hospital

🇺🇸

Edina, Minnesota, United States

Unity Hospital

🇺🇸

Fridley, Minnesota, United States

Minnesota Oncology Hematology PA-Maplewood

🇺🇸

Maplewood, Minnesota, United States

Hutchinson Area Health Care

🇺🇸

Hutchinson, Minnesota, United States

Saint John's Hospital - Healtheast

🇺🇸

Maplewood, Minnesota, United States

New Ulm Medical Center

🇺🇸

New Ulm, Minnesota, United States

North Memorial Medical Health Center

🇺🇸

Robbinsdale, Minnesota, United States

Metro-Minnesota CCOP

🇺🇸

Saint Louis Park, Minnesota, United States

Regions Hospital

🇺🇸

Saint Paul, Minnesota, United States

Park Nicollet Clinic - Saint Louis Park

🇺🇸

Saint Louis Park, Minnesota, United States

United Hospital

🇺🇸

Saint Paul, Minnesota, United States

Saint Francis Regional Medical Center

🇺🇸

Shakopee, Minnesota, United States

Ridgeview Medical Center

🇺🇸

Waconia, Minnesota, United States

Lakeview Hospital

🇺🇸

Stillwater, Minnesota, United States

Rice Memorial Hospital

🇺🇸

Willmar, Minnesota, United States

Minnesota Oncology and Hematology PA-Woodbury

🇺🇸

Woodbury, Minnesota, United States

Cooper Hospital University Medical Center

🇺🇸

Camden, New Jersey, United States

Toledo Clinic Cancer Centers-Bowling Green

🇺🇸

Bowling Green, Ohio, United States

Hematology Oncology Center Incorporated

🇺🇸

Elyria, Ohio, United States

Community Health Partners Regional Medical Center

🇺🇸

Elyria, Ohio, United States

North Coast Cancer Care-Clyde

🇺🇸

Clyde, Ohio, United States

Lima Memorial Hospital

🇺🇸

Lima, Ohio, United States

Toledo Clinic Cancer Centers-Maumee

🇺🇸

Maumee, Ohio, United States

Fisher-Titus Medical Center

🇺🇸

Norwalk, Ohio, United States

Saint Charles Hospital

🇺🇸

Oregon, Ohio, United States

Toledo Clinic Cancer Centers-Oregon

🇺🇸

Oregon, Ohio, United States

North Coast Cancer Care

🇺🇸

Sandusky, Ohio, United States

Mercy Hospital of Tiffin

🇺🇸

Tiffin, Ohio, United States

Flower Hospital

🇺🇸

Sylvania, Ohio, United States

The Toledo Hospital/Toledo Children's Hospital

🇺🇸

Toledo, Ohio, United States

Toledo Community Hospital Oncology Program CCOP

🇺🇸

Toledo, Ohio, United States

Saint Vincent Mercy Medical Center

🇺🇸

Toledo, Ohio, United States

University of Toledo

🇺🇸

Toledo, Ohio, United States

Mercy Saint Anne Hospital

🇺🇸

Toledo, Ohio, United States

Toledo Clinic Cancer Centers-Toledo

🇺🇸

Toledo, Ohio, United States

Fulton County Health Center

🇺🇸

Wauseon, Ohio, United States

Geisinger Medical Center

🇺🇸

Danville, Pennsylvania, United States

Geisinger Medical Center-Cancer Center Hazelton

🇺🇸

Hazleton, Pennsylvania, United States

Geisinger Medical Group

🇺🇸

State College, Pennsylvania, United States

Geisinger Wyoming Valley

🇺🇸

Wilkes-Barre, Pennsylvania, United States

Fredericksburg Oncology Inc

🇺🇸

Fredericksburg, Virginia, United States

UW Cancer Center Johnson Creek

🇺🇸

Johnson Creek, Wisconsin, United States

University of Wisconsin Hospital and Clinics

🇺🇸

Madison, Wisconsin, United States

Eastern Cooperative Oncology Group

🇺🇸

Boston, Massachusetts, United States

Abbott-Northwestern Hospital

🇺🇸

Minneapolis, Minnesota, United States

Hennepin County Medical Center

🇺🇸

Minneapolis, Minnesota, United States

The Jewish Hospital

🇺🇸

Cincinnati, Ohio, United States

MetroHealth Medical Center

🇺🇸

Cleveland, Ohio, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Butler Memorial Hospital

🇺🇸

Butler, Pennsylvania, United States

Presbyterian - Saint Lukes Medical Center - Health One

🇺🇸

Denver, Colorado, United States

Rose Medical Center

🇺🇸

Denver, Colorado, United States

The Medical Center of Aurora

🇺🇸

Aurora, Colorado, United States

Porter Adventist Hospital

🇺🇸

Denver, Colorado, United States

Exempla Saint Joseph Hospital

🇺🇸

Denver, Colorado, United States

Colorado Cancer Research Program CCOP

🇺🇸

Denver, Colorado, United States

Methodist Medical Center of Illinois

🇺🇸

Peoria, Illinois, United States

Boulder Community Hospital

🇺🇸

Boulder, Colorado, United States

Illinois Valley Hospital

🇺🇸

Peru, Illinois, United States

Sky Ridge Medical Center

🇺🇸

Lone Tree, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath